688319.SHG Chengdu Olymvax Biopharmaceuticals Inc. A
- Market cap
- CNY 11.4B
- P/E
- -
- P/B
- 12.60x
- ROE
- -7.6%
- Dividend yield
- 0.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688319.SHG undervalued?
Graham numberThe Graham number of Chengdu Olymvax Biopharmaceuticals Inc. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chengdu Olymvax Biopharmaceuticals Inc. A fundamental analysis
No fundamental analysis for Chengdu Olymvax Biopharmaceuticals Inc. A yet.
Chengdu Olymvax Biopharmaceuticals Inc. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.
Full company profileChengdu Olymvax Biopharmaceuticals Inc. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chengdu Olymvax Biopharmaceuticals Inc. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 161K | 44.7M | 76.3M | 179M | 320M | 487M | 547M | 496M | 589M | 704M | 723M |
| Gross Profit | 160K | 40.3M | 64.6M | 163M | 302M | 459M | 504M | 459M | 559M | 704M | 663M |
| Operating Income | -56.7M | -5.29M | -21.2M | -33.2M | 33.1M | 102M | 41.6M | 3.10M | 21.3M | 30.9M | 136M |
| EBITDA | -46.3M | 10.3M | -9.41M | -15.1M | 54.7M | 132M | 74.1M | 50.0M | 64.8M | 59.8M | 69.5M |
| Net Income | -55.5M | 676K | -19.0M | -31.0M | 36.1M | 108M | 26.6M | 17.6M | 20.8M | 22.2M | -65.7M |
| EPS | -0.29 | 0.00 | -0.09 | -0.09 | 0.10 | 0.28 | 0.07 | 0.04 | 0.05 | 0.05 | -0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 204M | 271M | 282M | 488M | 641M | 1.21B | 1.48B | 1.61B | 1.81B | 2.02B | 2.10B |
| Total Liabilities | 18.5M | 57.4M | 87.9M | 147M | 264M | 367M | 587M | 682M | 874M | 1.12B | 1.23B |
| Shareholders' Equity | 180M | 213M | 194M | 341M | 377M | 845M | 882M | 917M | 925M | 904M | 869M |
| Cash & Short-term Investments | 3.99M | 6.48M | 11.5M | 95.6M | 114M | 454M | 359M | 362M | 242M | 247M | 233M |
| Total Debt | - | - | 20.0M | 5.00M | 25.0M | 38.3M | 134M | 238M | 274M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -42.6M | -21.5M | -16.7M | -41.8M | 21.1M | 40.0M | -24.5M | 44.0M | -9.73M | 105M | - |
| Capital Expenditure | 6.81M | 15.7M | 18.1M | 29.2M | 38.8M | 69.7M | 201M | 170M | 207M | 98.8M | 49.2M |
| Free Cash Flow | -49.4M | -37.2M | -34.8M | -71.0M | -17.8M | -29.7M | -225M | -126M | -217M | 6.68M | -190M |
| Ratios | |||||||||||
| ROE | -30.8% | 0.3% | -9.8% | -9.1% | 9.6% | 12.8% | 3.0% | 1.9% | 2.2% | 2.5% | -7.6% |
| ROA | -27.2% | 0.2% | -6.7% | -6.4% | 5.6% | 8.9% | 1.8% | 1.1% | 1.1% | 1.1% | -3.1% |
| Net Profit Margin | -34,430.8% | 1.5% | -24.9% | -17.3% | 11.3% | 22.2% | 4.9% | 3.5% | 3.5% | 3.2% | -9.1% |
| Debt to Equity | - | - | 0.10x | 0.01x | 0.07x | 0.05x | 0.15x | 0.26x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chengdu Olymvax Biopharmaceuticals Inc. A dividends
- Dividend yield
- 0.13%
- Forward dividend
- -
- Payout ratio
- 66.2%
- Ex-dividend date
- Jun 25, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 14.7M | 0.04 | 66.2% |
| 2024 | CNY 29.7M | 0.07 | 143.0% |
| 2023 | CNY 5.99M | 0.01 | 34.1% |
| 2022 | CNY 4.25M | 0.01 | 16.0% |
| 2021 | CNY 1.03M | 0.00 | 1.0% |
| 2020 | CNY 755K | 0.00 | 2.1% |
| 2019 | CNY 494K | 0.00 | - |
| 2018 | 400K | 0.00 | - |
| 2017 | 97.0K | 0.00 | 14.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Chengdu Olymvax Biopharmaceuticals Inc. A
- Insiders 36.69%
- Institutions 9.64%
- Public & others 53.67%
- Shares outstanding 405M
- Free float 258M
Chengdu Olymvax Biopharmaceuticals Inc. A company profile
- Company name
- Chengdu Olymvax Biopharmaceuticals Inc. A
- Ticker
- 688319.SHG
- ISIN
- CNE1000051H8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 436
- Fiscal year end
- December
- Address
- No. 99 Tianxin Road, Chengdu, China, 611731
- Phone
- 86 28 6936 1111
- Website
- olymvax.com
About Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.
Chengdu Olymvax Biopharmaceuticals Inc. A management
5- Mr. Shaowen FanChairman of the Board & GM · born 1953
- Mr. Yong TanCFO & Deputy GM · born 1974
- Ms. Aimin ChenDirector & Deputy GM · born 1955
- Mr. Wei WuSecretary of the Board & Deputy GM · born 1982
- Mr. Xingyao QinAccounting supervisor · born 1973